CA-VERIMATRIX
3.6.2024 17:51:30 CEST | Business Wire | Press release
Regulatory News:
VERIMATRIX (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today is pleased to announce the initiation of coverage by Portzamparc.
Portzamparc initiates the coverage of VERIMATRIX with a study entitled: «Towards recurring and protected income », giving a BUY recommendation and a Target Price of € 0.55, compared to a closing price of € 0.45 on May 31, 2024.
The research will be available on the VERIMATRIX website: https://investors.verimatrix.com/
VERIMATRIX will also participate to the MID & SMALL CAPS conference organized by Portzamparc, on June 11, 2024.
This coverage will improve the stock market visibility and enrich the consensus of financial analysts, with ODDO BHF, which already covers the stock.
Upcoming events:
Shareholders’ Meeting: 13 June
Publication of H2 2024 revenue and results: 25 July 2024 (after market)
About Verimatrix
Verimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content, applications, and devices with intuitive, people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports, to sensitive financial and healthcare data, to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster, scale easily, protect valuable revenue streams, and win new business. Visit https://www.verimatrix.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603978420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Biologics Union Holds First Rally, Warns of May 1 Strike22.4.2026 13:56:00 CEST | Press release
Union estimates about 2,200 participants at one-hour event outside Bio Campus 1 Samsung Biologics’ labor union held its first rally on Tuesday and said it would move ahead with a strike on May 1 if management continues to reject meaningful talks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422754766/en/ Union members gather at a rally organized by the Samsung Biologics labor union outside Bio Campus 1 in Songdo, Incheon, on April 22, ahead of a planned May 1 strike. The rally, held for about an hour outside the main gate of the company’s Bio Campus 1 in Songdo, drew about 2,200 participants, according to the union. The event marks an escalation in a labor dispute that union leaders say is no longer limited to a small number of bargaining items, but instead concerns broader questions about accountability and decision-making within the company. Park Jaesung, chair of the Samsung Biologics union, said management had faile
HCL Group and UpLink Launch Fifth Global Aquapreneur Innovation Challenge to Advance Future Water Systems22.4.2026 13:16:00 CEST | Press release
HCL Group, in partnership with UpLink - the early-stage innovation initiative of the World Economic Forum - has launched the fifth global challenge under the Aquapreneur Innovation Initiative, titled Transforming Water Systems. Applications will be open from 22 April to 4 June 2026. The top 10 winners will receive a total financial award of CHF 1.75 million. For details on eligibility and application criteria, visit: UpLink - Transforming Water Systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421866128/en/ The Aquapreneur Innovation Initiative is a five-year, CHF 15 million collaboration between UpLink, HCL Group, and the World Economic Forum’s Food and Water Initiative, focused on building a global innovation ecosystem for freshwater solutions. Important Dates to Note 22 April to 4 June 2026 Open for submissions July to August 2026 Review and selection process January 2027 Announcement of the winners As water syst
Veristat to Acquire Certara’s Regulatory and Medical Writing Business22.4.2026 13:00:00 CEST | Press release
Strategic acquisition expands and enhances Veristat’s regulatory services to help more clinical trial sponsors develop novel, life-saving therapies across complex disease areas Veristat (the “Company”), a science-first full-service CRO and consultancy that advances complex therapies through the drug development lifecycle to regulatory submission, announced today its intended acquisition of Certara’s Regulatory and Medical Writing business. The team that will join Veristat is known for its white-glove advisory services and deep expertise authoring clinical and non-clinical documents throughout the drug development lifecycle. The acquisition is supported by WindRose Health Investors, LLC, a New York-based healthcare private equity firm, which remains a partner in driving Veristat's growth trajectory and mission. Notably, the acquisition expands Veristat’s regulatory writing and submission capabilities by adding more than 200 industry experts. Combined with the strong track record and mar
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 622.4.2026 12:01:00 CEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capa
Smartstream Research Reveals Five Realities Redefining Buy-Side Reconciliations22.4.2026 10:05:00 CEST | Press release
Key Facts Over 70% of firms still rely primarily on end-of-day reconciliation, while 53% cite timing differences and data mismatches as the leading causes of breaks. 59% of participants identified external data dependencies as the primary risk, while 47% highlighted internal inconsistencies. And 41% struggle with incomplete or insufficiently enriched data. 69% describe their T+1 model as partially adapted and still evolving. Whilst 41% say T+1 has made data quality a critical priority. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces new findings from its latest industry research report, Smart Reconciliations: The Buy-Side Perspective, highlighting the structural shifts transforming reconciliation, control, and operational confidence across buy-side firms. Based on insights gathered from a roundtable of senior operations leaders across asset management and investment firms, the report identifies five critical re
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom